JOURNAL ARTICLE

B - 61 Psilocybin as a First-Line Treatment of ADHD in Adult Populations.

  • Published In: Archives of Clinical Neuropsychology, 2024, v. 39, n. 7. P. 1154 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Perry, James; Young, Cara; WIlliams, Julie 3 of 3

Abstract

This article focuses on the potential use of psilocybin as a first-line treatment for attention deficit hyperactivity disorder (ADHD) in adults. It reviews literature comparing traditional stimulant medications, which target dopamine and noradrenaline receptors but often cause significant side effects, with microdosing psilocybin, which acts on serotonin receptors and may present fewer adverse effects. The review highlights psilocybin's neurological mechanisms and its promise as an alternative treatment when stimulant medications are ineffective or poorly tolerated. Limitations of current stimulant treatments are also discussed.

Additional Information

  • Source:Archives of Clinical Neuropsychology. 2024/10, Vol. 39, Issue 7, p1154
  • Document Type:Abstract
  • Subject Area:Education
  • Publication Date:2024
  • ISSN:0887-6177
  • DOI:10.1093/arclin/acae067.222
  • Accession Number:184163513
  • Copyright Statement:Copyright of Archives of Clinical Neuropsychology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.